Overview
Myelodysplastic syndromes (MDS) are a group of bone‑marrow disorders in which the marrow produces abnormal blood cells that die prematurely. Intermediate‑risk MDS refers to patients whose disease falls in the middle of the prognostic spectrum—more aggressive than low‑risk disease but not yet high‑risk for rapid progression to acute myeloid leukemia (AML).
- Who it affects: Most patients are adults over age 60; however, younger adults can be diagnosed, especially after exposure to radiation or chemotherapy.
- Prevalence: In the United States, MDS accounts for about 10–15 % of all hematologic cancers, with an estimated 15,000–20,000 new cases each year [CDC]. Approximately 30–40 % of these are classified as intermediate‑risk based on the Revised International Prognostic Scoring System (IPSS‑R).
- Prognosis: Median overall survival for intermediate‑risk patients is 3–5 years, though outcomes vary widely depending on age, cytogenetics, and response to therapy [1].
Symptoms
Because MDS is a disorder of the blood‑forming cells, symptoms reflect deficiencies in one or more blood lineages.
- Fatigue & weakness – caused by anemia (low red‑cell count). Patients often describe feeling “tired all the time” despite adequate rest.
- Shortness of breath – especially on exertion, due to reduced oxygen‑carrying capacity.
- Pallor – noticeable in the skin, lips, or nail beds.
- Easy bruising or petechiae – result of thrombocytopenia (low platelets); skin may show small red spots.
- Frequent or severe infections – neutropenia (low neutrophils) impairs the body’s ability to fight bacteria and fungi.
- Bleeding tendencies – gum bleeding, nosebleeds, heavy menstrual periods, or prolonged bleeding after cuts.
- Bone pain or discomfort – some patients report a dull ache in the hips, ribs, or spine, reflecting marrow expansion.
- Unexplained weight loss – can be a sign of disease progression or underlying inflammatory state.
- Fever without obvious source – may indicate infection related to neutropenia.
Causes and Risk Factors
The exact cause of most MDS cases is unknown, but several factors increase risk.
Acquired (non‑inherited) factors
- Previous chemotherapy or radiation therapy – especially alkylating agents (e.g., cyclophosphamide) or topoisomerase II inhibitors (e.g., etoposide). The latency period is usually 5‑10 years.
- Environmental exposures – benzene, certain pesticides, and industrial solvents have been linked to DNA damage in hematopoietic stem cells.
- Smoking – chronic tobacco use elevates the risk of MDS by 1.5‑2‑fold.
- Chronic immune or inflammatory conditions – e.g., rheumatoid arthritis, inflammatory bowel disease, or long‑term immunosuppressive therapy.
Inherited (genetic) predispositions
- Familial MDS/AML syndromes – mutations in genes such as RUNX1, GATA2, CEBPA, or SRP72 can be passed down.
- Congenital bone‑marrow failure syndromes – e.g., Fanconi anemia, dyskeratosis congenita.
Other risk modifiers
- Age ≥ 60 years (the single strongest risk factor).
- Male sex – men develop MDS about 1.5 times more often than women.
Diagnosis
Diagnosing intermediate‑risk MDS requires a combination of clinical evaluation, laboratory testing, and marrow examination.
Laboratory studies
- Complete blood count (CBC) with differential – shows cytopenias (low counts) in one or more lineages.
- Peripheral blood smear – reveals dysplastic (abnormally shaped) red cells, neutrophils, or platelets.
- Serum chemistry – assesses organ function before therapy (e.g., liver, kidney).
Bone‑marrow evaluation
- Aspiration and biopsy – the cornerstone. Pathologists look for:
- Percentage of blasts (myeloblasts) – intermediate‑risk typically 5‑9 %.
- Degree of dysplasia in >10 % of cells in any lineage.
- Cellularity (hyper‑ or hypocellular marrow).
- Cytogenetic analysis (karyotyping) – detects chromosomal abnormalities that influence prognosis (e.g., del(5q), +8, complex karyotype).
- Molecular testing – Next‑generation sequencing panels identify mutations in genes such as TP53, ASXL1, SF3B1, which help refine risk.
Prognostic scoring
The Revised International Prognostic Scoring System (IPSS‑R) incorporates blast percentage, cytogenetics, and depth of cytopenias to classify patients into five risk groups. Intermediate‑risk disease is split into:
- Intermediate‑Risk (IPSS‑R 1.5–2.0)
- Intermediate‑Risk (IPSS‑R 2.0–3.0) – sometimes called “intermediate‑2.”
Treatment Options
Treatment aims to improve blood counts, reduce transfusion dependence, delay progression to AML, and maintain quality of life. Choices depend on age, comorbidities, specific genetic findings, and patient preferences.
Supportive care (baseline for all patients)
- Blood transfusions – red‑cell units for symptomatic anemia; platelet transfusions for counts < 10 × 10⁹/L or active bleeding.
- Growth factors
- Erythropoiesis‑stimulating agents (ESAs) such as epoetin alfa for anemia, especially when serum erythropoietin < 500 mIU/mL.
- Granulocyte colony‑stimulating factor (G‑CSF) for neutropenia with recurrent infections.
- Antibiotic/antifungal prophylaxis – indicated for prolonged neutropenia (< 0.5 × 10⁹/L).
- Iron chelation therapy – deferasirox or deferoxamine for patients receiving ≥ 20 red‑cell units per year to prevent organ damage.
Disease‑modifying therapies
- Hypomethylating agents (HMAs) – the mainstay for intermediate‑risk MDS.
- Azacitidine (5‑azacytidine) – given subcutaneously or intravenously for 7 days each 28‑day cycle. Improves overall survival (median 24 months vs 15 months with supportive care) [3].
- Decitabine – similar schedule; may be combined with venetoclax in selected cases.
- Immunomodulatory drugs (IMiDs) – lenalidomide is highly effective in the isolated del(5q) subtype but can also be used off‑label for other intermediate-risk cases.
- Targeted therapy
- Venetoclax (BCL‑2 inhibitor) combined with HMAs for patients with TP53 or complex karyotype disease, based on emerging phase II data.
- Clinical trials of IDH1/2 inhibitors for patients harboring those mutations.
Curative‑intent options
- Allogeneic hematopoietic stem‑cell transplantation (allo‑HSCT) – the only potentially curative therapy. Candidates are usually ≤ 70 years with acceptable organ function and a suitable donor. Reduced‑intensity conditioning regimens have expanded eligibility.
- Clinical trial enrollment – essential for many intermediate‑risk patients, as novel agents (e.g., oral HMAs, splice‑osome inhibitors) are under investigation.
Lifestyle and adjunct measures
- Balanced diet rich in iron‑rich foods (if not iron‑overloaded) and adequate protein to support hematopoiesis.
- Regular, moderate exercise (walking, yoga) to combat fatigue and maintain cardiovascular health.
- Avoidance of tobacco and excessive alcohol, both of which can worsen cytopenias.
- Vaccinations: annual influenza, pneumococcal (PCV20 or PPSV23), and COVID‑19 boosters.
Living with Intermediate‑Risk Myelodysplastic Syndrome
Managing day‑to‑day life involves both medical monitoring and practical self‑care strategies.
Monitoring schedule
- Every 1–3 months – CBC, transfusion requirements, and symptom review.
- Every 6 months – bone‑marrow reassessment if there are changes in blood counts or new symptoms.
Practical tips
- Keep a symptom diary – note fatigue levels, fevers, bruising, or infections; this helps the care team adjust therapy quickly.
- Plan for transfusions – arrange a reliable schedule with a local blood center; consider home transfusion services if available.
- Infection prevention – practice hand hygiene, avoid crowded places during flu season, and wear masks if neutropenic.
- Manage fatigue – schedule activities for times of day when energy is highest, use assistive devices (canes, walkers) if needed, and incorporate short naps.
- Psychosocial support – join MDS support groups, seek counseling, and involve caregivers in decision‑making.
- Financial navigation – work with hospital social workers to explore insurance coverage for costly drugs like HMAs or transplant.
Prevention
Because many cases are sporadic, absolute prevention is impossible, but risk can be lowered.
- Avoid known carcinogens – limit exposure to benzene (e.g., gasoline fumes, industrial solvents) and wear protective equipment if occupational exposure is unavoidable.
- Use chemotherapy judiciously – discuss with oncologists the long‑term hematologic risks when considering alkylating agents.
- Quit smoking – smoking cessation programs cut the relative risk by ~30 %.
- Vaccinate appropriately – reduces infections that can trigger marrow stress.
- Regular health check‑ups – early detection of cytopenias allows prompt work‑up before disease progresses.
Complications
If left untreated or inadequately managed, intermediate‑risk MDS can lead to serious health problems.
- Progression to acute myeloid leukemia (AML) – occurs in 20‑30 % of intermediate‑risk patients within 2–5 years.
- Severe infections – neutropenia predisposes to bacteremia, fungal pneumonia, and sepsis.
- Bleeding emergencies – uncontrolled hemorrhage from gastrointestinal lesions or intracranial bleeding due to thrombocytopenia.
- Iron overload – from chronic red‑cell transfusions; can cause cardiomyopathy, liver cirrhosis, endocrine dysfunction.
- Quality‑of‑life decline – chronic fatigue, depression, and functional dependence.
- Secondary cancers – especially in patients previously exposed to chemotherapy or radiation.
When to Seek Emergency Care
Call 911 or go to the nearest emergency department immediately if you experience any of the following:
- Sudden, severe shortness of breath or chest pain.
- Uncontrolled bleeding (e.g., heavy nosebleed, bleeding gums, blood in urine or stool) that does not stop after applying pressure for 10 minutes.
- High fever (≥ 38.5 °C / 101.3 °F) that lasts more than 24 hours or is accompanied by chills, severe headache, or confusion.
- Sudden severe weakness, dizziness, or fainting.
- Rapidly worsening fatigue with a heart rate > 120 bpm (possible anemia‑related tachycardia).
- Signs of infection with low neutrophil count (e.g., red streaks from a wound, severe sore throat, painful urination) especially if you are neutropenic.
Early treatment of these emergencies can be life‑saving.
References:
[1] Greenberg PL et al. “Myelodysplastic Syndromes.” Nat Rev Dis Primers. 2021.
[2] Malcovati L et al. “Revised IPSS for MDS: Validation and Clinical Utility.” Blood. 2022.
[3] Fenaux P et al. “Azacitidine Improves Survival in MDS: A Randomized Controlled Trial.” J Clin Oncol. 2010.
CDC. “Myelodysplastic Syndromes Surveillance.” 2023.
Mayo Clinic. “Myelodysplastic syndrome.” Accessed May 2024.
NIH/NCI. “Adult Acute Myeloid Leukemia Treatment (PDQ®)‑Health Professional Version.” 2023.